PIRIDE M 1 TAB by Dr Precision is a clinically formulated fixed-dose combination tablet containing Glimepiride 1 mg and Metformin Hydrochloride 500 mg in a sustained-release form, specifically designed for effective management of Type 2 Diabetes Mellitus. This formulation synergistically targets both insulin secretion and insulin sensitivity to provide comprehensive blood glucose control. Glimepiride stimulates pancreatic beta cells to release insulin with glucose-dependent action, minimizing hypoglycemia risks, while sustained-release Metformin enhances peripheral glucose uptake and reduces hepatic glucose production, improving glycemic control with enhanced gastrointestinal tolerability. Manufactured by Bluepill Express in WHO-GMP and ISO-certified facilities, PIRIDE M 1 TAB guarantees high-quality production standards, therapeutic consistency, and patient-friendly dosing suitable for once-daily administration. Its advanced formulation addresses core pathophysiological aspects of Type 2 Diabetes, making it highly efficient for patients inadequately controlled with monotherapy or requiring initial dual therapy. The sustained-release Metformin component ensures steady drug plasma levels, reducing side effects and improving adherence. This product is essential for B2B pharmaceutical distributors, healthcare providers, and clinics seeking reliable, GMP-compliant antidiabetic medication that combines efficacy, safety, and convenience for optimal diabetes management.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Glimepiride 1 mg and Metformin Hydrochloride 500 mg (sustained-release) |
| Indication | Type 2 Diabetes Mellitus requiring dual therapy for improved glycemic control |
| Mechanism of Action | Glimepiride stimulates insulin secretion; Metformin improves insulin sensitivity and reduces hepatic glucose production |
| Dosage Form | Oral sustained-release tablet |
| Dosing Frequency | Once daily, preferably with the first major meal |
| Manufacturing Standards | Produced by Bluepill Express in WHO-GMP and ISO-certified facilities |
| Quality Assurance | Undergoes rigorous quality control for assay, dissolution, uniformity, stability |
| Therapeutic Benefits | Effective fasting and postprandial blood glucose control with reduced hypoglycemia risk |
| Patient Compliance | Sustained-release formulation enhances GI tolerability and convenience |
| Packaging and Label | Marketed under Dr Precision label ensuring GMP-compliant precision formulation |
| Attributes | Description |
|---|---|
| Glimepiride Content | 1 mg per tablet |
| Metformin Hydrochloride Content | 500 mg per tablet in sustained-release form |
| Tablet Weight | Approximate standard oral tablet weight (specific weight not provided) |
| Pharmacological Class | Sulfonylurea (Glimepiride) and Biguanide (Metformin) |
| Release Profile | Sustained-release for Metformin component |
| Administration Route | Oral |
| Shelf Life | As per pharmaceutical standards (typically 24-36 months, check packaging) |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Compliance Standards | WHO-GMP and ISO certified manufacturing |
| Packaging Type | Blister packs or bottles as per market requirements |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The sustained-release Metformin in PIRIDE M 1 TAB ensures a gradual and steady release of the drug, which helps reduce peak plasma concentrations that can cause gastrointestinal side effects. This improved tolerability enhances patient adherence and maintains consistent blood glucose control.
Yes, PIRIDE M 1 TAB is designed as a fixed-dose combination ideal for patients who are inadequately controlled on monotherapy or as an initial dual therapy to achieve better glycemic control.
PIRIDE M 1 TAB is manufactured by Bluepill Express in WHO-GMP and ISO-certified facilities, ensuring high-quality production standards, consistency, and compliance with international pharmacopeial requirements.
Glimepiride’s insulin secretion stimulation is glucose-dependent, meaning it primarily activates only when blood glucose levels are elevated, thereby reducing the incidence of hypoglycemia compared to older sulfonylureas.
Using PIRIDE M 1 TAB combines both drugs into a single once-daily tablet, improving patient compliance, ensuring consistent dosing, and leveraging the synergistic mechanism for better glycemic control with fewer side effects owing to the sustained-release Metformin.
Country Of Origin: India
PIRIDE M 1 TAB is a fixed-dose combination of Glimepiride 1 mg and Metformin Hydrochloride 500 mg (sustained release), used to treat Type 2 Diabetes Mellitus. It offers a dual mechanism for controlling blood sugar—enhancing insulin secretion and improving insulin sensitivity. Manufactured by Bluepill Express in certified facilities, it ensures international quality, therapeutic consistency, and reliable glycemic control.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
PIRIDE M 1 TAB is a fixed-dose oral antidiabetic medication that combines two powerful agents: Glimepiride 1 mg and Metformin Hydrochloride 500 mg in sustained-release form. This synergistic formulation is designed to provide comprehensive glycemic control in patients with Type 2 Diabetes Mellitus who are either inadequately controlled on monotherapy or are initiating dual therapy for better results.
Glimepiride belongs to the sulfonylurea class and stimulates the release of insulin from functional pancreatic beta cells. Its action is glucose-dependent, meaning it enhances insulin secretion primarily in the presence of elevated blood glucose levels, thus reducing the risk of hypoglycemia compared to older sulfonylureas. Metformin, a biguanide, complements this effect by improving insulin sensitivity, decreasing hepatic glucose production, and enhancing peripheral glucose uptake. The sustained-release format of Metformin in PIRIDE M 1 TAB ensures a steady and prolonged action with improved gastrointestinal tolerability.
This combination targets the core pathophysiological defects in Type 2 Diabetes, namely insulin resistance and beta-cell dysfunction. Glimepiride acts on the pancreas, while Metformin primarily acts on the liver and muscle tissues. As a result, PIRIDE M 1 TAB offers a well-rounded pharmacological approach that improves fasting and postprandial blood glucose levels. It is suitable for once-daily dosing, typically administered with the first major meal of the day, making it convenient for long-term use and improving patient adherence.
Bluepill Express ensures the manufacturing of PIRIDE M 1 TAB in WHO-GMP and ISO-certified units, following stringent quality control protocols. Each tablet undergoes rigorous testing for assay, dissolution, uniformity, and stability, ensuring therapeutic accuracy and compliance with international pharmacopeial standards. The sustained-release technology used in Metformin production offers improved gastrointestinal tolerability, reduced peak plasma fluctuations, and enhanced patient comfort, especially in those starting dual therapy.
PIRIDE M 1 TAB is indicated for adults with Type 2 Diabetes Mellitus where diet, exercise, and single-drug regimens have not resulted in adequate glycemic control. It may also be considered a first-line treatment in cases where initial blood glucose levels are significantly elevated. Clinical studies have shown that fixed-dose combinations like PIRIDE M 1 reduce glycemic variability and may provide cardiovascular and metabolic benefits when used appropriately.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
